Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD
Nucleocytoplasmic transport and nuclear pore disruption in ALS/FTD
批准号:
9896868
负责人:
Thomas E. Lloyd
金额:
$65.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-15 至 2022-03-31
关键词:
ALS patientsAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis PathwayAntisense OligonucleotidesBiochemicalBiological ModelsBrainC9ORF72Cell LineCell modelCellsCharacteristicsDataDefectDevelopmentDipeptidesDiseaseDisease MarkerDisease modelDrosophila genusFamilial Amyotrophic Lateral SclerosisFrontotemporal DementiaFunctional disorderFutureGeneticHealthHumanImageImmunofluorescence ImmunologicMediatingModelingMorphologyMotor NeuronsMusNatureNerve DegenerationNeurogliaNeuronsNuclearNuclear ExportNuclear ImportNuclear Localization SignalNuclear PoreNuclear Pore ComplexNuclear Pore Complex ProteinsPathogenesisPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPorphyrinsProcessProtein Export PathwayProtein ImportProteinsRNARNA-Binding ProteinsSeriesShort Interspersed Nucleotide ElementsSystemTestingTherapeuticTissuesTranslatingTranslationsValidationYeastsbrain tissuecell typedrug actiondrug discoveryflyfrontotemporal lobar dementia-amyotrophic lateral sclerosisfunctional disabilitygain of functionhuman diseasein vivoinduced pluripotent stem cellinhibitor/antagonistmouse modelneurotoxicitynovelnovel strategiesnovel therapeuticsnucleocytoplasmic transportphotoreceptor degenerationrestorationsmall moleculetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
A GGGGCC hexanucleotide repeat expansion (HRE) in C9ORF72 is the most common genetic cause of
familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), though the underlying disease
mechanism is poorly defined. Multiple studies, including our own, support a gain-of-function mechanism of
neurotoxicity mediated by the HRE. Expanded repeats may generate toxic RNAs that sequester RNA-binding
proteins. They may also be translated via Repeat-Associated Non-ATG Translation (RANT) into toxic dipeptide
repeat proteins (DPRs). Both HRE RNA and DPRs are hypothesized to mediate neurotoxicity in C9-ALS/FTD.
Multiple recent studies from our lab and others suggest that disruption of the nuclear pore and/or
nucleocytoplasmic transport is a primary cause of neurodegeneration in yeast, fly, and induced pluripotent cell
(iPS) models of C9- ALS/FTD. In addition, our recent studies, using a C9-ALS/FTD Drosophila model, human
iPS neurons derived from C9-ALS patients, and human C9-ALS CNS tissues, suggest that nucleocytoplasmic
transport defects may be a fundamental pathway for ALS/FTD pathogenesis amenable to therapy.
This proposal will comprehensively investigate the mechanism by which the C9ORf72 HRE disrupts
nucleocytoplasmic transport and nuclear pores utilizing several complementary models including C9-ALS fly
and mouse models and iPS neurons and brain tissue from C9 ALS/FTD patients, and investigate whether
modulation of nucleocytoplasmic transport may be a therapeutic strategy for ALS/FTD. (1) We will determine
the morphological and biochemical composition of the nuclear pore complex (NPC) in motor neurons and glia,
and characterize NPC pathology in C9-ALS/FTD in fly, iPS, mouse models and human brain. Little is known
about CNS NPCs including differences between cell types and ultimately how the NPC constituents,
nucleoporins, are dysregulated in C9-ALS/FTD models. Therefore, understanding the basic characteristics of
the NPC and nucleocytoplasmic transport in the CNS and in disease models is fundamentally important to
dissecting the nature of pathology. (2) We will then investigate the mechanism of nucleocytoplasmic transport
disruption in C9-ALS/FTD. We hypothesize that disrupted NPC and/or nucleocytoplasmic transport function
causes neurodegeneration due to nuclear loss and/or cytoplasmic accumulation of nuclear export sequence
(NES) containing cargo in fly, mouse, and iPS models of C9-ALS. (3) Therefore, we will determine the
consequences of nucleocytoplasmic transport disruption in C9-ALS/FTD models. (4) Finally, we will determine
if restoration of nucleocytoplasmic transport rescues neurodegeneration in C9-ALS/FTD by employing a series
of novel compounds that may have human utility.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s40478-021-01150-5
发表时间:
2021-03-19
期刊:
Acta neuropathologica communications
影响因子:
7.1
作者:
[Coyne AN, Rothstein JD]
通讯作者:
Rothstein JD
Neuronal cell-cycle re-entry and neurodegeneration
-
批准号:10027420
-
项目类别:
-
资助金额:$66.58万
-
财政年份:2020
-
负责人:Thomas E. Lloyd
-
依托单位:
Neuronal cell-cycle re-entry and neurodegeneration
-
批准号:10410469
-
项目类别:
-
资助金额:$65.97万
-
财政年份:2020
-
负责人:Thomas E. Lloyd
-
依托单位:
Neuronal cell-cycle re-entry and neurodegeneration
-
批准号:10659116
-
项目类别:
-
资助金额:$65.97万
-
财政年份:2020
-
负责人:Thomas E. Lloyd
-
依托单位:
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.
-
批准号:10199942
-
项目类别:
-
资助金额:$44.83万
-
财政年份:2020
-
负责人:Thomas E. Lloyd
-
依托单位:
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.
-
批准号:10633289
-
项目类别:
-
资助金额:$46.21万
-
财政年份:2020
-
负责人:Thomas E. Lloyd
-
依托单位:
Dynactin function in axons, synapses, and neurodegenerative disease
-
批准号:8650929
-
项目类别:
-
资助金额:$35.08万
-
财政年份:2013
-
负责人:Thomas E. Lloyd
-
依托单位:
Dynactin function in axons, synapses, and neurodegenerative disease
-
批准号:9022533
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2013
-
负责人:Thomas E. Lloyd
-
依托单位:
Dynactin function in axons, synapses, and neurodegenerative disease
-
批准号:8482528
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2013
-
负责人:Thomas E. Lloyd
-
依托单位:
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
-
批准号:8268467
-
项目类别:
-
资助金额:$17.56万
-
财政年份:2008
-
负责人:Thomas E. Lloyd
-
依托单位:
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
-
批准号:8079726
-
项目类别:
-
资助金额:$17.56万
-
财政年份:2008
-
负责人:Thomas E. Lloyd
-
依托单位:
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
-
批准号:7513545
-
项目类别:
-
资助金额:$17.56万
-
财政年份:2008
-
负责人:Thomas E. Lloyd
-
依托单位:
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
-
批准号:7632243
-
项目类别:
-
资助金额:$17.56万
-
财政年份:2008
-
负责人:Thomas E. Lloyd
-
依托单位:
A Drosophila model of motor neuron disease using mutations in P150 / Dynactin.
-
批准号:7892368
-
项目类别:
-
资助金额:$17.56万
-
财政年份:2008
-
负责人:Thomas E. Lloyd
-
依托单位:
海外基金